A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3813
Abstract: Effective second‐line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form of S‐1. In the phase I… read more here.
Keywords: biliary tract; resminostat; study; histone deacetylase ... See more keywords
Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.22775
Abstract: Resminostat, a novel class I, IIb, and IV histone deacetylase inhibitor, was studied in advanced hepatocellular carcinoma (HCC) patients after relapse to sorafenib (SHELTER study). In this phase I/II clinical trial, combination of sorafenib and… read more here.
Keywords: hepatocellular carcinoma; sorafenib induced; hcc; induced apoptosis ... See more keywords